Major Depression - Multicenter Double Blind Randomized Controlled Trial for Tolerability, Safety and Efficacy of the H-Coil dTMS - Completed
22 medical centers in the USA, Canada, Europe and Israel
16 September, 2009
A multicenter clinical trial for the assessment of the efficacy and safety of deep brain rTMS in subjects suffering from major depression disorder (MDD) has begun in 22 medical centers in the USA, Canada, Europe and Israel. Enrollment of patients has begun in six sites.
Cocaine Addiction - Double-Blind Placebo Control Safety and Feasibility Study
Columbia University, New York, NY, USA
2 January, 2011
A clinical trial of Brainsway's Deep TMS device for the treatment of cocaine withdrawal has begun at Columbia University, New York. The trial will be performed by the Research Foundation for Mental Hygiene, Inc., a research center which operates in collaboration with Columbia University. The effects of Deep TMS will be assessed using PET scanning to monitor metabolic processes in the body. The trial will follow a double-blind design with a control group.
Multiple Sclerosis - Double-Blind Placebo Control Safety and Feasibility Study
Charité University, Berlin, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
21 March, 2010
A clinical trial of Brainsway's Deep TMS for the treatment of multiple sclerosis patients (MS) has begun in two leading medical centers in Germany: the Charité Hospital – considered to be the leading university hospital in Berlin, and the University Medical Center Hamburg-Eppendorf, in Hamburg.
Stroke Rehabilitation - Double-Blind Placebo Control Safety and Feasibility Study
Hadassah Medical Organization, Jerusalem, Israel.
1 March, 2009
A clinical trial using Brainsway's Deep TMS device for the rehabilitation of stroke patients has begun.
The trial is designed determine the safety and efficacy of deep transcranial magnetic stimulation (TMS) in treating acute ischemic stroke (stroke resulting from a blood clot in the brain).
Smoking Cessation in Chronic Obstructive Pulmonary Disease - Double-Blind Placebo Control Safety and Feasibility Study
Be'er Ya'akov Mental Health Center, Israel
1 July, 2009
A clinical trial for the assessment of the efficacy of Deep TMS in inducing smoking cessation in chronic obstructive pulmonary disease patients, has begun at the Mental Health Center in Be'er Ya'akov, Israel.
Schizophrenia Negative Symptoms - Double-Blind Placebo Control Safety and Feasibility Study
Shalvata Mental Health Center, Hod Hasharon, Israel
9 March, 2009
A double-blind placebo-controlled clinical trial utilizing the Brainsway's Deep TMS device for the treatment of negative symptoms in 45 patients with schizophrenia has begun at the Shalvata Mental Health Center.
Bipolar Disorder - Double-Blind Placebo Control Safety and Feasibility Study
Shalvata Mental Health Center, Hod-Hasharon, Israel
13 January, 2009
A double-blinded and placebo-controlled clinical trial has begun at the Shalvata Mental Health Center to explore the efficacy and safety of Deep TMS in 50 subjects with bipolar depression, currently treated with mood stabilizers and previously unsuccessfully treated with antidepressant medication.
Autism - Double-Blind Placebo Control Safety and Feasibility Study
The Alfred Hospital and Monash University, Melbourne, Australia
12 February, 2008
Brainsway Ltd. (the "Company") is pleased to announce that on this day, February 12th 2008, it has entered into an agreement with the Alfred Psychiatry Research Centre in Melbourne, Australia (the "Alfred Centre") to perform human clinical trials.
Parkinson's Disease - Double-Blind Placebo Control Safety and Feasibility Study
Sheba Medical Center, Tel Hashomer , Israel
28 January, 2008
A clinical trial using Brainsway's Deep TMS device for the treatment of Parkinson’s disease has begun at the Sheba Medical Center at Tel Hashomer, Israel.
40 patients are expected to take part in the trial
Home
Site Map
Contact Us
Send to a friend
Print page